Israeli Pharma Company Wavelength Appoints New CEO
Pharma veteran Iftach Seri was named as Wavelength’s CEO. Formerly a Perrigo subsidiary, the company was recently sold to New York-based investment firm SK Capital for $110 million
Wavelength Pharmaceuticals Ltd. appointed Iftach Seri as its new CEO, the company announced Wednesday. The company also appointed Tami Cohen as chief financial officer.
For daily updates, subscribe to our newsletter by clicking here.
Wavelength is a former subsidiary of pharma company Perrigo Company PLC. Last week, Perrigo announced that it has completed the sale of its Israel-based active pharmaceutical ingredients (API) business to New York-based investment firm SK Capital for $110 million. Perrigo API was renamed Wavelength Pharmaceuticals.
Drugs (illustration)
Originally called Chemagis, Wavelength Pharmaceuticals has around 350 employees in Israel, with some supporting staff in the U.S. and India.
Before joining Wavelength, Mr. Seri held an executive position at Mumbai-headquartered Sun Pharmaceutical Industries Ltd. and served as CEO of Israeli drugstore chain New Pharm. Ms. Cohen previously served as CFO of Israeli drinks company SodaStream International Ltd.
- Fresh Teva Lawsuit Goes Against Dividends Paid by Debt Heavy Drugmaker
- Japan's Orix, Mitsubishi Tanabe Pharma Considering Additional Israeli Investments
- Biomed Company Protalix to Lay Off a Fifth of its Workforce
SK Capital invests mainly in the domains of specialty materials, chemicals, and pharmaceuticals. The company has over $1.9 billion assets under management and says its portfolio companies currently generate annual revenues of approximately $6 billion.
